The 80th Annual Meeting of the Japanese Society of Hematology

Presentation information

Print

Luncheon Seminar

LS3-1

New Treatment Strategies for R/R ALL
～ Blinatumomab:Bispecific T-Cell Engager(BiTE®) as new immunotherapy ～

Sun. Oct 14, 2018 11:45 AM - 12:30 PM No.1 (Osaka International Convention Center, 5F Main Hall)

Chair: Yukio Kobayashi (International University of Health and Welfare, Mita Hospital)

Sponsors: Amgen Astellas BioPharma K.K./Astellas Pharma Inc.

[LS3-1] New Treatment Strategies for R/R ALL
～ Blinatumomab:Bispecific T-Cell Engager(BiTE®) as new immunotherapy ～

Elias Jabbour (Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX)